Boston Scientific Corp. (BSX)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.56 (+0.63%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Boston Scientific Corp. (BSX)
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Key Insights

Critical company metrics and information
  • Share Price

    $89.39
  • Market Cap

    $131.75 Billion
  • Total Outstanding Shares

    1.47 Billion Shares
  • Total Employees

    48,000
  • Dividend

    No dividend
  • IPO Date

    May 18, 1992
  • SIC Description

    Surgical & Medical Instruments & Apparatus
  • Homepage

    https://www.bostonscientific.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities$2.94 Billion
Net Cash Flow From Financing Activities$1.61 Billion
Net Cash Flow From Investing Activities, Continuing$-3.04 Billion
Net Cash Flow From Investing Activities$-3.04 Billion
Net Cash Flow, Continuing$1.51 Billion
Net Cash Flow From Operating Activities, Continuing$2.94 Billion
Net Cash Flow From Financing Activities, Continuing$1.61 Billion
Net Cash Flow$1.52 Billion
Exchange Gains/Losses$2.00 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income/Loss From Continuing Operations After Tax$1.79 Billion
Costs And Expenses$13.71 Billion
Interest Expense, Operating$290.00 Million
Selling, General, and Administrative Expenses$5.75 Billion
Diluted Average Shares$2.97 Billion
Cost Of Revenue$4.94 Billion
Preferred Stock Dividends And Other Adjustments$0.00
Net Income/Loss Attributable To Parent$1.79 Billion
Nonoperating Income/Loss$-310.00 Million
Income Tax Expense/Benefit$414.00 Million
Other Operating Expenses$2.71 Billion
Income/Loss From Continuing Operations Before Tax$2.20 Billion
Net Income/Loss Attributable To Noncontrolling Interest$-18.00 Million
Net Income/Loss Available To Common Stockholders, Basic$1.79 Billion
Basic Average Shares$2.95 Billion
Gross Profit$10.97 Billion
Basic Earnings Per Share$1.22
Benefits Costs and Expenses$13.71 Billion
Operating Expenses$8.46 Billion
Net Income/Loss$1.79 Billion
Operating Income/Loss$2.51 Billion
Revenues$15.91 Billion
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Diluted Earnings Per Share$1.21

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Other Current Assets$6.01 Billion
Current Liabilities$5.91 Billion
Fixed Assets$3.07 Billion
Other Non-current Assets$20.49 Billion
Equity Attributable To Parent$20.71 Billion
Equity$20.96 Billion
Noncurrent Liabilities$11.21 Billion
Noncurrent Assets$29.32 Billion
Assets$38.08 Billion
Liabilities And Equity$38.08 Billion
Accounts Payable$907.00 Million
Inventory$2.75 Billion
Liabilities$17.12 Billion
Current Assets$8.76 Billion
Intangible Assets$5.75 Billion
Equity Attributable To Noncontrolling Interest$248.00 Million
Other Current Liabilities$3.89 Billion
Wages$1.11 Billion

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Related Companies

View additional S&P 500 companies similar to Boston Scientific Corp. (BSX)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.